Alliance Healthcare Group

alliancehealthcare.com.sg

Alliance is a reliable medical brand trusted by more than 1,000,000 individuals in the region, a healthcare organisation specialising in corporate health solutions, a leading wholesale pharmaceutical company facilitating timely access of cutting-edge medications to the region, and a safe haven where our patients can count on their friendly family doctors and medical specialists to treat their health problems. As a physician-led and physician-owned healthcare organisation, we know what is important to those who matter to us – our patients. Since our inception, quality healthcare and evidence-based medical treatment for our patients have always been our priorities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

OPTEL ACQUIRES PHARMA TRACK-AND-TRACE UNIT OF KÖRBER

OPTEL Group | January 12, 2022

news image

OPTEL GROUP, already a world leader in supply chain traceability, is expanding its expertise and global reach with the recent acquisition of the track-and-trace unit of the Körber Business Area Pharma, formerly known as Traxeed, based in Germany. Körber is a leading international technology group. The acquisition, announced today, will allow OPTEL to leverage the unit's expertise in pharmaceutical and agrochemical track-and-trace technologies, provide the company wit...

Read More

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

news image

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More

Business Insights

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

news image

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More
news image

Business Insights

OPTEL ACQUIRES PHARMA TRACK-AND-TRACE UNIT OF KÖRBER

OPTEL Group | January 12, 2022

OPTEL GROUP, already a world leader in supply chain traceability, is expanding its expertise and global reach with the recent acquisition of the track-and-trace unit of the Körber Business Area Pharma, formerly known as Traxeed, based in Germany. Körber is a leading international technology group. The acquisition, announced today, will allow OPTEL to leverage the unit's expertise in pharmaceutical and agrochemical track-and-trace technologies, provide the company wit...

Read More
news image

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More
news image

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More
news image

Business Insights

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us